In addition to palbociclib, ribociclib and abemaciclib were subsequently developed and approved by the FDA for the treatment of patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer (67). The gene discussed is ERBB2; the disease is breast carcinoma.